iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
83.90
-4.01 (-4.56%)
Dec 3, 2024, 1:59 PM EST - Market open
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $147.54M in the quarter ending September 30, 2024, with 18.41% growth. This brings the company's revenue in the last twelve months to $560.03M, up 18.45% year-over-year. In the year 2023, iRhythm Technologies had annual revenue of $492.68M with 19.90% growth.
Revenue (ttm)
$560.03M
Revenue Growth
+18.45%
P/S Ratio
4.87
Revenue / Employee
$280,013
Employees
2,000
Market Cap
2.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
Dec 31, 2019 | 214.55M | 67.28M | 45.68% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Select Medical Holdings | 6.97B |
QuidelOrtho | 2.82B |
Concentra Group Holdings Parent | 1.88B |
Privia Health Group | 1.72B |
ACADIA Pharmaceuticals | 929.24M |
Warby Parker | 742.53M |
Catalyst Pharmaceuticals | 460.48M |
Zai Lab | 355.75M |
IRTC News
- 12 days ago - iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference - GlobeNewsWire
- 15 days ago - iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring - GlobeNewsWire
- 27 days ago - iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device - GlobeNewsWire
- 4 weeks ago - iRhythm Technologies Announces Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy - GlobeNewsWire
- 6 weeks ago - With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says - Benzinga